By Jack W. Plunkett
Buy new: $299.99
First tagged by Jack W. Plunkett
Customer tags: investing, biotechnology, economics, finance, marketing, globalization, genetics, innovation, business, entrepreneurship, genomics, healthcare
Review & Description
PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC 2012
Key Features:
-Industry trends analysis, market data and competitive intelligence
-Market forecasts and Industry Statistics
-Industry Associations and Professional Societies List
-In-Depth Profiles of hundreds of leading companies
-Industry Glossary
-Buyer may register for access to search and export data at Plunkett Research Online
Pages: 554
Statistical Tables Provided: 18
Companies Profiled: 367
Geographic Focus: Global
A complete market research report, including forecasts and market estimates, technologies analysis and developments at innovative firms.
You will gain vital insights that can help you shape your own strategy for business development, product development and investments.
-How is the industry evolving?
-How is the industry being shaped by new technologies?
-How is demand growing in emerging markets and mature economies?
-What is the size of the market now and in the future?
-What are the financial results of the leading companies?
-What are the names and titles of top executives?
Contents, Statistics, Forecasts and Analysis Include:
Major Trends Affecting the Biotech & Genetics Industry
-Ethanol Production Soars, But U.S. Federal Subsidy in Question
-Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms
-From India to Singapore to China, Nations Compete Fiercely in Biotech Development
-Clinical Trials and Medical Records Processing in India Spark Concerns
-Gene Therapies and Patients Genetic Profiles Promise a Personalized Approach to Medicine
-Breakthrough Drugs for Cancer Treatment, Many More Will Follow
-Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age
-Biogenerics (Follow-on Biologics) are in Limbo in the U.S.
-Breakthrough New Drug Delivery Systems Evolve
-Stem Cells: Multiple Sources Stem from New Technologies
-U.S. Government Stance on Funding for New Stem Cell Research Unclear
-Stem Cells: Therapeutic Cloning Techniques Advance
-Stem Cells: A New Era of Regenerative Medicine Takes Shape
-Nanotechnology Converges with Biotech
-Agricultural Biotechnology Scores Breakthroughs but Causes Controversy
-Focus on Vaccines
-Technology Discussion: Genomics
-Technology Discussion: Proteomics
-Technology Discussion: Microarrays
-Technology Discussion: DNA Chips
-Technology Discussion: SNPs (Snips)
-Technology Discussion: Combinatorial Chemistry
-Technology Discussion: Synthetic Biology
-Technology Discussion: Recombinant DNA
-Technology Discussion: Polymerase Chain Reaction (PCR)
Biotech & Genetics Industry Statistics
-U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2010
-U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals:1993-2009
-Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2010
-Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2009-2011
-U.S. Exports & Imports of Pharmaceutical Products: 2006-1st Quarter 2011
-U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: Selected Calendar Years, 2004-2019
-Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Year 2010-2012
-Global Area of Biotech Crops by Country: 2010
-Biologics & Biotechnology R&D, PhRMA Member Companies: 2009
-Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2010
-Sales By Geographic Area, PhRMA Member Companies: 2009
-Domestic U.S. Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2009
-Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1970-2010 Read more
No comments:
Post a Comment